Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors

Cell Reports

Volumn 24, Issue 7, 2018, Pages 1802-1815.e5

  Kuzmina, Natalia A ^a,b   Younan, Patrick ^a,b   Gilchuk, Pavlo ^d   Santos, Rodrigo I ^a,b   Flyak, Andrew I ^c,e   Ilinykh, Philipp A ^a,b   Huang, Kai ^a,b   Lubaki, Ndongala M ^a,b   Ramanathan, Palaniappan ^a,b   Crowe, James E ^c,d   Bukreyev, Alexander ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Department of Pathology   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e California Institute of Technology   (United States)

Author keywords

antibody; Ebola virus; enhancement of infection; epitope; FC receptor; filovirus

Indexed keywords

EPITOPE; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; ANTISERUM; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY ISOLATION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; HUMAN; HUMAN CELL; MARBURG HEMORRHAGIC FEVER; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; THP-1 CELL LINE; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECT; EBOLAVIRUS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MARBURGVIRUS; METABOLISM; MONOCYTE; MORTALITY; PATHOGENICITY; PRIMARY CELL CULTURE; REPORTER GENE; SURVIVAL ANALYSIS; SURVIVOR; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; EBOLAVIRUS; EPITOPES; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN FC FRAGMENTS; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; MICE, INBRED BALB C; MONOCYTES; PRIMARY CELL CULTURE; RECEPTORS, IGG; SURVIVAL ANALYSIS; SURVIVORS; THP-1 CELLS; VIRAL ENVELOPE PROTEINS;

EID: 85051108967     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.07.035     Document Type: Article

References (85)

1. Acosta, E.G., Bartenschlager, R., Paradoxical role of antibodies in dengue virus infections: Considerations for prophylactic vaccine development. Expert Rev. Vaccines 15 (2016), 467–482.
2. Ana-Sosa-Batiz, F., Johnston, A.P., Liu, H., Center, R.J., Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Kim, J.H., Michael, N.L., et al. HIV-specific antibody-dependent phagocytosis matures during HIV infection. Immunol. Cell Biol. 92 (2014), 679–687.
3. Ana-Sosa-Batiz, F., Vanderven, H., Jegaskanda, S., Johnston, A., Rockman, S., Laurie, K., Barr, I., Reading, P., Lichtfuss, M., Kent, S.J., Influenza-specific antibody-dependent phagocytosis. PLoS ONE, 11, 2016, e0154461.
4. Aye, K.S., Charngkaew, K., Win, N., Wai, K.Z., Moe, K., Punyadee, N., Thiemmeca, S., Suttitheptumrong, A., Sukpanichnant, S., Prida, M., Halstead, S.B., Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum. Pathol. 45 (2014), 1221–1233.
5. Baize, S., Leroy, E.M., Georges-Courbot, M.C., Capron, M., Lansoud-Soukate, J., Debré P., Fisher-Hoch, S.P., McCormick, J.B., Georges, A.J., Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5 (1999), 423–426.
6. Bharat, T.A., Noda, T., Riches, J.D., Kraehling, V., Kolesnikova, L., Becker, S., Kawaoka, Y., Briggs, J.A., Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc. Natl. Acad. Sci. USA 109 (2012), 4275–4280.
7. Boonnak, K., Dambach, K.M., Donofrio, G.C., Tassaneetrithep, B., Marovich, M.A., Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J. Virol. 85 (2011), 1671–1683.
8. Bornholdt, Z.A., Turner, H.L., Murin, C.D., Li, W., Sok, D., Souders, C.A., Piper, A.E., Goff, A., Shamblin, J.D., Wollen, S.E., et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351 (2016), 1078–1083.
9. Borrok, M.J., Jung, S.T., Kang, T.H., Monzingo, A.F., Georgiou, G., Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 7 (2012), 1596–1602.
10. Boruchov, A.M., Heller, G., Veri, M.C., Bonvini, E., Ravetch, J.V., Young, J.W., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115 (2005), 2914–2923.
11. Bournazos, S., Ravetch, J.V., Fcγ receptor function and the design of vaccination strategies. Immunity 47 (2017), 224–233.
12. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., Huggins, J., A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178 (1998), 651–661.
13. Bruhns, P., Iannascoli, B., England, P., Mancardi, D.A., Fernandez, N., Jorieux, S., Daëron, M., Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113 (2009), 3716–3725.
14. Burk, R., Bollinger, L., Johnson, J.C., Wada, J., Radoshitzky, S.R., Palacios, G., Bavari, S., Jahrling, P.B., Kuhn, J.H., Neglected filoviruses. FEMS Microbiol. Rev. 40 (2016), 494–519.
15. Chan, K.R., Ong, E.Z., Mok, D.Z., Ooi, E.E., Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev. Anti Infect. Ther. 13 (2015), 1351–1360.
16. Clapham, H.E., Quyen, T.H., Kien, D.T., Dorigatti, I., Simmons, C.P., Ferguson, N.M., Modelling virus and antibody dynamics during dengue virus infection suggests a role for antibody in virus clearance. PLoS Comput. Biol., 12, 2016, e1004951.
17. Corti, D., Misasi, J., Mulangu, S., Stanley, D.A., Kanekiyo, M., Wollen, S., Ploquin, A., Doria-Rose, N.A., Staupe, R.P., Bailey, M., et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351 (2016), 1339–1342.
18. Davidson, E., Bryan, C., Fong, R.H., Barnes, T., Pfaff, J.M., Mabila, M., Rucker, J.B., Doranz, B.J., Mechanism of binding to ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 89 (2015), 10982–10992.
19. Dube, D., Schornberg, K.L., Stantchev, T.S., Bonaparte, M.I., Delos, S.E., Bouton, A.H., Broder, C.C., White, J.M., Cell adhesion promotes Ebola virus envelope glycoprotein-mediated binding and infection. J. Virol. 82 (2008), 7238–7242.
20. Durbin, A.P., Vargas, M.J., Wanionek, K., Hammond, S.N., Gordon, A., Rocha, C., Balmaseda, A., Harris, E., Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376 (2008), 429–435.
21. Dye, J.M., Herbert, A.S., Kuehne, A.I., Barth, J.F., Muhammad, M.A., Zak, S.E., Ortiz, R.A., Prugar, L.I., Pratt, W.D., Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. USA 109 (2012), 5034–5039.
22. Fibriansah, G., Ibarra, K.D., Ng, T.S., Smith, S.A., Tan, J.L., Lim, X.N., Ooi, J.S., Kostyuchenko, V.A., Wang, J., de Silva, A.M., et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349 (2015), 88–91.
23. Fleit, H.B., Kobasiuk, C.D., The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII. J. Leukoc. Biol. 49 (1991), 556–565.
24. Flipse, J., Wilschut, J., Smit, J.M., Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 14 (2013), 25–35.
25. Flyak, A.I., Ilinykh, P.A., Murin, C.D., Garron, T., Shen, X., Fusco, M.L., Hashiguchi, T., Bornholdt, Z.A., Slaughter, J.C., Sapparapu, G., et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160 (2015), 893–903.
26. Flyak, A.I., Shen, X., Murin, C.D., Turner, H.L., David, J.A., Fusco, M.L., Lampley, R., Kose, N., Ilinykh, P.A., Kuzmina, N., et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164 (2016), 392–405.
27. Flyak, A.I., Kuzmina, N., Murin, C.D., Bryan, C., Davidson, E., Gilchuk, P., Gulka, C.P., Ilinykh, P.A., Shen, X., Huang, K., et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat Microbiol. 3 (2018), 670–677.
28. Furuyama, W., Marzi, A., Carmody, A.B., Maruyama, J., Kuroda, M., Miyamoto, H., Nanbo, A., Manzoor, R., Yoshida, R., Igarashi, M., et al. Fcγ-receptor IIa-mediated Src signaling pathway is essential for the antibody-dependent enhancement of ebola virus infection. PLoS Pathog., 12, 2016, e1006139.
29. Geisbert, T.W., Hensley, L.E., Larsen, T., Young, H.A., Reed, D.S., Geisbert, J.B., Scott, D.P., Kagan, E., Jahrling, P.B., Davis, K.J., Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163 (2003), 2347–2370.
30. Gillis, C., Gouel-Chéron, A., Jönsson, F., Bruhns, P., Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies. Front. Immunol., 5, 2014, 254.
31. Gollins, S.W., Porterfield, J.S., Flavivirus infection enhancement in macrophages: An electron microscopic study of viral cellular entry. J. Gen. Virol. 66 (1985), 1969–1982.
32. Halstead, S.B., Antibody-dependent enhancement of infection: A mechanism for indirect virus entry into cells. Cold Spring Harbor Monograph Archive 28: Cellular Receptors for Animal Viruses, 1994, Cold Spring Harbor Laboratory Press, 493–516.
33. Halstead, S.B., O'Rourke, E.J., Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146 (1977), 201–217.
34. Halstead, S.B., O'Rourke, E.J., Allison, A.C., Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J. Exp. Med. 146 (1977), 218–229.
35. Henao-Restrepo, A.M., Longini, I.M., Egger, M., Dean, N.E., Edmunds, W.J., Camacho, A., Carroll, M.W., Doumbia, M., Draguez, B., Duraffour, S., et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
36. Hessell, A.J., Hangartner, L., Hunter, M., Havenith, C.E., Beurskens, F.J., Bakker, J.M., Lanigan, C.M., Landucci, G., Forthal, D.N., Parren, P.W., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007), 101–104.
37. Hezareh, M., Hessell, A.J., Jensen, R.C., van de Winkel, J.G., Parren, P.W., Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75 (2001), 12161–12168.
38. Higel, F., Seidl, A., Sörgel, F., Friess, W., N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur. J. Pharm. Biopharm. 100 (2016), 94–100.
39. Hogarth, P.M., Pietersz, G.A., Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11 (2012), 311–331.
40. Ilinykh, P.A., Shen, X., Flyak, A.I., Kuzmina, N., Ksiazek, T.G., Crowe, J.E. Jr., Bukreyev, A., Chimeric filoviruses for identification and characterization of monoclonal antibodies. J. Virol. 90 (2016), 3890–3901.
41. Jahrling, P.B., Geisbert, J.B., Swearengen, J.R., Larsen, T., Geisbert, T.W., Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196:Suppl 2 (2007), S400–S403.
42. Kou, Z., Lim, J.Y., Beltramello, M., Quinn, M., Chen, H., Liu, S., Martinez-Sobrido, L., Diamond, M.S., Schlesinger, J.J., de Silva, A., et al. Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology 410 (2011), 240–247.
43. Ksiazek, T.G., Rollin, P.E., Williams, A.J., Bressler, D.S., Martin, M.L., Swanepoel, R., Burt, F.J., Leman, P.A., Khan, A.S., Rowe, A.K., et al. Clinical virology of Ebola hemorrhagic fever (EHF): Virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179:Suppl 1 (1999), S177–S187.
44. Kudoyarova-Zubavichene, N.M., Sergeyev, N.N., Chepurnov, A.A., Netesov, S.V., Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J. Infect. Dis. 179:Suppl 1 (1999), S218–S223.
45. Kuhn, J.H., Filoviruses. First Edition, 2008, Springer.
46. Lee, J.E., Fusco, M.L., Hessell, A.J., Oswald, W.B., Burton, D.R., Saphire, E.O., Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454 (2008), 177–182.
47. Littaua, R., Kurane, I., Ennis, F.A., Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144 (1990), 3183–3186.
48. Liu, L., Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J. Pharm. Sci. 104 (2015), 1866–1884.
49. Liu, Y., Gao, X., Masuda, E., Redecha, P.B., Blank, M.C., Pricop, L., Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes. J. Immunol. 177 (2006), 8440–8447.
50. Lubaki, N.M., Ilinykh, P., Pietzsch, C., Tigabu, B., Freiberg, A.N., Koup, R.A., Bukreyev, A., The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J. Virol. 87 (2013), 7471–7485.
51. Lubaki, N.M., Younan, P., Santos, R.I., Meyer, M., Iampietro, M., Koup, R.A., Bukreyev, A., The Ebola interferon inhibiting domains attenuate and dysregulate cell-mediated immune responses. PLoS Pathog., 12, 2016, e1006031.
52. Martinez, O., Johnson, J.C., Honko, A., Yen, B., Shabman, R.S., Hensley, L.E., Olinger, G.G., Basler, C.F., Ebola virus exploits a monocyte differentiation program to promote its entry. J. Virol. 87 (2013), 3801–3814.
53. Martins, K.A., Jahrling, P.B., Bavari, S., Kuhn, J.H., Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev. Vaccines 15 (2016), 1101–1112.
54. McElroy, A.K., Akondy, R.S., Davis, C.W., Ellebedy, A.H., Mehta, A.K., Kraft, C.S., Lyon, G.M., Ribner, B.S., Varkey, J., Sidney, J., et al. Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. USA 112 (2015), 4719–4724.
55. Messaoudi, I., Amarasinghe, G.K., Basler, C.F., Filovirus pathogenesis and immune evasion: Insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13 (2015), 663–676.
56. Mire, C.E., Geisbert, J.B., Marzi, A., Agans, K.N., Feldmann, H., Geisbert, T.W., Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl. Trop. Dis., 7, 2013, e2600.
57. Mire, C.E., Geisbert, J.B., Borisevich, V., Fenton, K.A., Agans, K.N., Flyak, A.I., Deer, D.J., Steinkellner, H., Bohorov, O., Bohorova, N., et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci. Transl. Med., 9, 2017, eaai8711.
58. Morens, D.M., Venkateshan, C.N., Halstead, S.B., Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J. Gen. Virol. 68 (1987), 91–98.
59. Murin, C.D., Fusco, M.L., Bornholdt, Z.A., Qiu, X., Olinger, G.G., Zeitlin, L., Kobinger, G.P., Ward, A.B., Saphire, E.O., Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci. USA 111 (2014), 17182–17187.
60. Nakayama, E., Tomabechi, D., Matsuno, K., Kishida, N., Yoshida, R., Feldmann, H., Takada, A., Antibody-dependent enhancement of Marburg virus infection. J. Infect. Dis. 204:Suppl 3 (2011), S978–S985.
61. Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008), 34–47.
62. Olinger, G.G. Jr., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S.D., Johnson, A.K., Morton, J., et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. USA 109 (2012), 18030–18035.
63. Oswald, W.B., Geisbert, T.W., Davis, K.J., Geisbert, J.B., Sullivan, N.J., Jahrling, P.B., Parren, P.W., Burton, D.R., Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog., 3, 2007, e9.
64. Park, J.G., Isaacs, R.E., Chien, P., Schreiber, A.D., In the absence of other Fc receptors, Fc gamma RIIIA transmits a phagocytic signal that requires the cytoplasmic domain of its gamma subunit. J. Clin. Invest. 92 (1993), 1967–1973.
65. Pyankov, O.V., Setoh, Y.X., Bodnev, S.A., Edmonds, J.H., Pyankova, O.G., Pyankov, S.A., Pali, G., Belford, S., Lu, L., La, M., et al. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. Sci. Rep., 7, 2017, 41537.
66. Qiu, X., Alimonti, J.B., Melito, P.L., Fernando, L., Ströher, U., Jones, S.M., Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 141 (2011), 218–227.
67. Qiu, X., Audet, J., Wong, G., Pillet, S., Bello, A., Cabral, T., Strong, J.E., Plummer, F., Corbett, C.R., Alimonti, J.B., Kobinger, G.P., Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med., 4, 2012, 138ra81.
68. Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514 (2014), 47–53.
69. Qiu, X., Audet, J., Lv, M., He, S., Wong, G., Wei, H., Luo, L., Fernando, L., Kroeker, A., Fausther Bovendo, H., et al. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci. Transl. Med., 8, 2016, 329ra33.
70. Ramadhany, R., Hirai, I., Sasaki, T., Ono, K., Ramasoota, P., Ikuta, K., Kurosu, T., Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection. Antiviral Res. 124 (2015), 61–68.
71. Reusch, D., Tejada, M.L., Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 25 (2015), 1325–1334.
72. Rodrigo, W.W., Jin, X., Blackley, S.D., Rose, R.C., Schlesinger, J.J., Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J. Virol. 80 (2006), 10128–10138.
73. Sanchez, A., Trappier, S.G., Mahy, B.W., Peters, C.J., Nichol, S.T., The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 93 (1996), 3602–3607.
74. Ströher, U., West, E., Bugany, H., Klenk, H.D., Schnittler, H.J., Feldmann, H., Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75 (2001), 11025–11033.
75. Swisher, J.F., Feldman, G.M., The many faces of FcγRI: Implications for therapeutic antibody function. Immunol. Rev. 268 (2015), 160–174.
76. Takada, A., Watanabe, S., Okazaki, K., Kida, H., Kawaoka, Y., Infectivity-enhancing antibodies to Ebola virus glycoprotein. J. Virol. 75 (2001), 2324–2330.
77. Takada, A., Feldmann, H., Ksiazek, T.G., Kawaoka, Y., Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77 (2003), 7539–7544.
78. Takada, A., Ebihara, H., Feldmann, H., Geisbert, T.W., Kawaoka, Y., Epitopes required for antibody-dependent enhancement of Ebola virus infection. J. Infect. Dis. 196:Suppl 2 (2007), S347–S356.
79. Tay, M.Z., Liu, P., Williams, L.D., McRaven, M.D., Sawant, S., Gurley, T.C., Xu, T.T., Dennison, S.M., Liao, H.X., Chenine, A.L., et al. Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. PLoS Pathog., 12, 2016, e1005817.
80. Thommesen, J.E., Michaelsen, T.E., Løset, G.A., Sandlie, I., Brekke, O.H., Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol. Immunol. 37 (2000), 995–1004.
81. Towner, J.S., Paragas, J., Dover, J.E., Gupta, M., Goldsmith, C.S., Huggins, J.W., Nichol, S.T., Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332 (2005), 20–27.
82. Volchkov, V.E., Becker, S., Volchkova, V.A., Ternovoj, V.A., Kotov, A.N., Netesov, S.V., Klenk, H.D., GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214 (1995), 421–430.
83. Williams, K.L., Sukupolvi-Petty, S., Beltramello, M., Johnson, S., Sallusto, F., Lanzavecchia, A., Diamond, M.S., Harris, E., Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog., 9, 2013, e1003157.
84. Wilson, J.A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A.L., Hart, M.K., Epitopes involved in antibody-mediated protection from Ebola virus. Science 287 (2000), 1664–1666.
85. Zeitlin, L., Pettitt, J., Scully, C., Bohorova, N., Kim, D., Pauly, M., Hiatt, A., Ngo, L., Steinkellner, H., Whaley, K.J., Olinger, G.G., Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. USA 108 (2011), 20690–20694.